Dexfenfluramine Profile in Quantitative EEG and Its Topographical Aspects
Dexfenfluramine chlorhydrate (Isomeride) is a drug used for the treatment of obesity (Finer etal. 1985; Enzi etal. 1986). This compound reduces disorders of eating behavior, with a specific effect on diet selection, carbohydrate-rich meals being decreased while protein consumption is unaffected (Wurtman et al. 1985). Such a shift in diet selection can be produced experimentally by hypothalamic injection of serotonin (5-HT) (Blundell 1984; Leibowitz 1985). Dexfenfluramine is an indirect agonist of 5-HT, increasing its release and inhibiting its reuptake (Garattini etal. 1985). 5-HT terminals are widely distributed in the cerebral cortex, so dexfenfluramine could act on large brain areas. Such a general action can be studied by quantitative EEG (Q-EEG) and its brain mapping. The aim of this study is to describe the EEG variations induced by three different doses of dexfenfluramine in healthy young subjects.
KeywordsPlacebo Obesity Carbohydrate Serotonin Caffeine
Unable to display preview. Download preview PDF.
- Enzi G, Crepaldi G et al. (1986) Efficacy and safety of dextrofenfluramine in obese patients: a multicenter study. 15th CLINP Congress, Puerto Rico, 14–17 Dec 1986Google Scholar
- Finer N, Craddock D, Lavielle R, Keen H (1985) Dextrofenfluramine in the treatment of refractory obesity. Curr Ther Res 38:847–854Google Scholar
- Garattini S, Mennini T, Bendotti C, Invernizzi R, Samanin R (1985) Neurochemical mechanism of action of drugs which modify feedings via the serotoninergic system. Appetite 2 (Suppl): 15–38Google Scholar
- Leibowitz SF, Shor-Posner E (1986) Hypothalmic serotonin in control of eating behavior. In: Ferrari F, Brambilla F (eds) Disorders of eating behavior. Pergamon, Oxford, pp 343–352Google Scholar